The Institute for Clinical and Economic Review (ICER) has released its draft evidence report for mavacamten, a drug intended for use in patients with hypertrophic cardiomyopathy (HCM). HCM is a genetic disorder associated with an increased risk for sudden cardiac death. The drug was developed by MyoKardia and Bristol-Myers Squibb. Results from the analysis will be discussed at a meeting to be held in late October.
“Mavacamten reduces adenosine triphosphatase activity in cardiac myosin heavy chain, one of the proteins in heart muscle cells, and thus reduces the contraction of the heart that can contribute to obstruction…The Evidence Report will be the subject of a virtual public meeting of the CTAF on October 22, 2021. During the meeting, the independent council will vote on key questions raised in the report.” Read more here.
(Source: ICER, 8/18/21)